What this is
- How it works
- How it works isn't classified yet
- Tested for
- Esophageal Cancer
- Main trialPhase 3
- “This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively. Subjects are administered until disease progression assessed by the RECIST V1.1 standard (unless the…”In the company’s words, NCT04415853 on ClinicalTrials.gov
- Other names
- Larotinib · Lerotinib
Other drugs for Esophageal Cancer
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- DurvalumabAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up1
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | |
| Phase 1/2Completed | 13 Dec 2022 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | |
| Phase 1Terminated | 9 Sep 2021 | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | |
| Phase 1Completed | 10 Jan 2022 | ADME Study of [14C]- Larotinib in Healthy Male Subjects | |
| Phase 1Completed | 17 Feb 2022 | A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants | |
| Phase 1Withdrawn | 30 Dec 2026 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026